Daxxify: Recommendations for Treatment

Patients' desires for aesthetics treatments that are safe, effective, and longer lasting have shaped innovation in BotulinumtoxinA (BoNTA). Daxibotulinumtoxin A (DaxiBoNTA), recently approved by the Food and Drug Administration in 2022, contains a synthetic stabilizing excipient that improves efficacy and extends duration. The potential advantage of fewer treatments coupled with its superior diffusion and rapid onset has led many patients and clinicians to consider transitioning to this BoNTA. This article highlights the differences between commercially available BoNTA's, Daxi-BoNTA's physical attributes that contribute to its favorable clinical profile, and the indications, methods, and considerations for transitioning patients to this new BoNTA.